tcsc1094 Roxadustat

Roxadustat (FG-4592) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor developed for the treatment of anemia.

In Vitro: Roxadustat significantly increases accumulation of HIF-1α and BNIP3, resultes in reduced TUNEL-positive photoreceptors 3 days after RD and an increased thickness of the outer nuclear layer 7 days after RD in the TUNEL-positive cells^[1]. Roxadustat increases differentiation of adipose-derived mesenchymal stem cells (ADMSCs) under both hypoxia and normoxia^[2].

In Vivo: Roxadustat (25 mg/kg) enhances mitophagy and attenuates retinal histopathologic damage in the photoreceptor layer after RD in an RD animal model^[1].